Cargando…
Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
BACKGROUND: Market Access Agreements (MAA) between pharmaceutical industry and health care payers have been proliferating in Europe in the last years. MAA can be simple discounts from the list price or very sophisticated schemes with inarguably high administrative burden. DISCUSSION: We distinguishe...
Autores principales: | Jarosławski, Szymon, Toumi, Mondher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203045/ https://www.ncbi.nlm.nih.gov/pubmed/21982545 http://dx.doi.org/10.1186/1472-6963-11-259 |
Ejemplares similares
-
New drug regulations in France: what are the impacts on market access? Part 2 – impacts on market access and impacts for the pharmaceutical industry
por: Rémuzat, Cécile, et al.
Publicado: (2013) -
CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs
por: Lexchin, Joel, et al.
Publicado: (2014) -
Drug repurposing in pharmaceutical industry and its impact on market access: market access implications
por: Murteira, Susana, et al.
Publicado: (2014) -
Current process and future path for health economic assessment of pharmaceuticals in France
por: Toumi, Mondher, et al.
Publicado: (2015) -
Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
por: Badora, Karolina, et al.
Publicado: (2017)